Melanocortin Peptides (regulatory overview)

Melanocortin peptides: chemistry, receptors, and the Australian regulatory picture

Somewhere between my second long run of the week and a particularly absorbing true-crime episode, I started pulling apart the melanocortin literature again. I'd been meaning to write this up for months. The melanocortin system is genuinely one of the more elegant pieces of peptide biology , a single precursor protein giving rise to a whole family of signalling molecules, each one shaped by a different processing enzyme, each one finding its own receptor in a different tissue. Pharmacologically, it's a delight. Regulatory-wise, in Australia, it's a minefield , and I think that distinction is worth being clear about from the start.

This article covers what melanocortin peptides are, where they come from structurally, how researchers classify them, and what the Therapeutic Goods Administration (TGA) has to say about their supply in Australia. No performance framing. No anti-ageing angles. Just the science and the law.

What is a melanocortin peptide?

Melanocortin peptides are a family of small signalling molecules derived from a single large precursor protein called pro-opiomelanocortin, or POMC. POMC is expressed primarily in the anterior pituitary and in certain neurons of the hypothalamus, but also in peripheral tissues including skin and immune cells. Post-translational processing , the cleavage and modification of POMC by tissue-specific enzymes called prohormone convertases; yields a range of peptide fragments depending on where in the body the cleavage occurs.

The major melanocortin peptides produced from POMC include adrenocorticotropic hormone (ACTH), alpha-melanocyte-stimulating hormone (α-MSH), beta-MSH, and gamma-MSH. Each of these is, in structural terms, a peptide, a short chain of amino acids connected by peptide bonds. α-MSH, for example, is a tridecapeptide: 13 amino acids long. ACTH, in contrast, is 39 amino acids. Small structural differences matter enormously here; the specific sequence and any post-translational modifications determine which melanocortin receptor (MCR) subtype a given peptide binds to, and with what affinity.

The melanocortin receptor family

Five melanocortin receptor subtypes have been identified and characterised: MC1R through MC5R. All five are G protein-coupled receptors (GPCRs) that, when activated, primarily signal through adenylyl cyclase and cyclic AMP. Their distribution differs substantially across tissue types, which is part of why the melanocortin system is involved in such a wide range of physiological processes.

MC1R is expressed in melanocytes and is central to the regulation of skin and hair pigmentation, it is the original "melanocortin" function and the one that gives the peptide family its name. MC2R is the primary receptor for ACTH and is expressed almost exclusively in the adrenal cortex, where it plays a role in cortisol synthesis. MC3R and MC4R are expressed in the brain, particularly in the hypothalamus, and have been the subject of substantial research interest related to energy homeostasis and feeding behaviour. MC5R has a broader peripheral distribution and has been studied in relation to exocrine gland function.

Importantly, the endogenous melanocortin peptides act as agonists at these receptors. There is also a naturally occurring antagonist; agouti-related protein (AgRP), which competes with α-MSH at MC3R and MC4R. This agonist-antagonist balance is part of why the system has attracted so much interest from researchers studying metabolic signalling.

Synthetic analogues and the research landscape

Because the endogenous melanocortin peptides are relatively short-lived in circulation, rapid enzymatic degradation is a persistent challenge in peptide pharmacology, something I've spent a fair bit of time on when writing about pharmacokinetics; researchers have worked to develop synthetic analogues with modified structures intended to improve stability or receptor selectivity. The modifications are typically at the level of individual amino acids, sometimes incorporating D-amino acids (which resist protease activity) or cyclisation strategies.

Some of the better-known synthetic melanocortin analogues in the research literature include Melanotan I (afamelanotide) and Melanotan II, along with a range of more selective experimental compounds. Afamelanotide does have a specific regulatory history in Australia, which I'll cover below. Melanotan II and most other synthetic analogues do not.

The research literature on melanocortin analogues spans pigmentation biology, neuroscience, and metabolic physiology. It's genuinely interesting science. But the gap between "this has been studied in a controlled research setting" and "this is safe, approved and legal to supply in Australia" is enormous, and I think it bears repeating: that gap is not a technicality. It's where the regulatory framework sits for very good reasons.

Australian regulatory classification

This is the part that matters practically. The Australian regulatory framework for peptides, including melanocortin analogues, is governed by the TGA under the Therapeutic Goods Act 1989 and the Poisons Standard (the current instrument is the Standard for the Uniform Scheduling of Medicines and Poisons, or SUSMP).

Afamelanotide has a specific and narrow approved pathway in Australia. It is listed on the Australian Register of Therapeutic Goods (ARTG) for one indication under strict conditions. That approval does not extend to any other melanocortin peptide, and it does not mean the class is broadly accessible.

For the vast majority of synthetic melanocortin analogues, including Melanotan II and the many analogues circulating in grey-market and online supplement spaces, there is no TGA approval, no ARTG listing, and no legal pathway for general supply in Australia. The TGA has been actively enforcing against the supply of unapproved peptides. Supplying an unapproved therapeutic good in Australia is an offence under the Therapeutic Goods Act 1989, carrying substantial penalties.

A practitioner seeking to access an unapproved melanocortin peptide for a specific patient would need to navigate either the Special Access Scheme (Category B, for individual patients) or apply through the Authorised Prescriber scheme. These pathways require clinical justification, appropriate oversight, and regulatory approval; they are not a general licence to supply. Outside of these frameworks, supply of unapproved peptide products is illegal. Full stop.

Honestly, I'd argue the volume of misleading information circulating online about melanocortin peptides, the framing of unregulated analogues as if they're simply "research chemicals" outside of regulatory reach, is a more serious public health issue than it's often treated. The TGA's enforcement posture on peptides has sharpened considerably, and the risk sits with suppliers, yes, but also increasingly with anyone facilitating access.

POMC, peptide processing, and a note on complexity

One thing I want to stress, because it tends to get flattened in non-specialist writing: the melanocortin system does not operate in isolation. POMC processing also produces beta-endorphin and met-enkephalin; opioid peptides with their own distinct receptor pharmacology. The tissue-specific cleavage of POMC means that the same gene product generates very different signalling molecules depending on location. A pituitary cell and a skin keratinocyte produce different fragments from the same precursor.

This complexity is part of why developing selective melanocortin-targeted therapies is genuinely difficult, and why the history of the field is littered with compounds that showed initial promise in narrow models but ran into problems when tested in more complete biological contexts. Selectivity across five receptor subtypes, in a system with multiple endogenous ligands and an antagonist, is a hard problem.

For anyone who wants to build on this with the broader context of how peptide-based signalling differs from small-molecule pharmacology, the GLP-1 receptor agonist class offers an instructive comparison, another GPCR-targeting peptide family with a very different regulatory pathway and a fully approved drug landscape. The structural pharmacology challenges have some parallels even if the biology is completely different. Route of administration matters too; many peptides require subcutaneous injection precisely because oral bioavailability is poor, a function of first-pass degradation that applies here as much as anywhere. See our piece on first-pass metabolism for more on that mechanism.

Where the research sits now

Published peer-reviewed work on melanocortin receptor pharmacology is substantial. MC4R in particular has attracted significant research interest given its central role in energy balance signalling. A number of compounds have entered early-phase human trials, though none with a broad approved indication in Australia as of the time of writing.

The picture for MC1R-targeted compounds is a little different: afamelanotide's approved pathway represents the furthest-progressed regulatory outcome for any melanocortin analogue in Australia, and even that sits within a tightly defined indication with specialist-only prescribing.

For the rest of the class; experimental analogues, research-grade compounds, grey-market peptides sold under any number of names, the regulatory position is clear. Unapproved, and the TGA is enforcing. That's not a caveat buried at the end of an article. That's the starting point.

Sources

• Therapeutic Goods Act 1989, Therapeutic Goods Administration (TGA)
• Melanocortin System; StatPearls, National Center for Biotechnology Information (NCBI)
• Peptide regulatory guidance, Therapeutic Goods Administration (TGA)
• The melanocortin system and its role in energy homeostasis, NCBI PMC, peer-reviewed

, Priya Nandakumar, Pharmacology writer; peptides & PK